News

Study evaluates the impact of surgical procedure on visual outcomes in patients.

See what ranked most popular in our top 10 stories of 2020.

A new gene therapy for this patient population targets the ND4 gene mutation.

Check out the latest cartoon!

Amid ramped up production of vaccines, CARES Act gives FDA power to head off potential drug shortfalls. Prevent Blindness is urging the FDA to use its authority to ensure TED treatment drug supply isn’t interrupted.

BIGH3 is an extracellular matrix protein that can act in an autocrine, paracrine manner.

Spaceflight-associated neuro-ocular syndrome a potential challenge during long missions.

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Amydis announced the successful completion of a pre-investigational new drug (IND) meeting with the FDA for its candidate AMDX-2011P, a small-molecule retinal tracer that targets amyloid beta to diagnosis amyloid angiopathy.

Imaging ciliary muscle details mechanism of accommodation, effects of aging .

Two teams of researchers from Gyroscope Therapeutics and the University of Pennsylvania are joining forces to explore gene therapy targets for three specific serious eye diseases.

Cynthia Matossian, MD, FACS, ABES, discusses the big disconnect between signs and symptoms of ocular surface disease, including meibomian gland dysfunction, and why a clear process for educating patients and initiating treatment is essential.

Tamara R. Fountain, MD, will serve as president of the American Academy of Ophthalmology after being elected by the organization’s community of ophthalmologists during its recent virtual annual meeting.

Study results could provide a new preferred treatment paradigm for this population.

Topline data following completion of ALTISSIMO trial treatment phase expected in second quarter of 2021.

The investigational RNA therapy is designed to address the underlying cause of Leber congenital amaurosis 10 due to a mutation in the CEP290 gene.

New options open possibilities for treatment, resulting in better outcomes for patients.

ViGeneron and Biogen this week have announced a global collaboration and licensing agreement in which the partners will develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors that treat inherited eye disease.

Pandemic forces some to reconsider careers.

Roche’s faricimab is the focus of Yosemite and Rhine studies, which investigators say show it has the potential to offer lasting vision improvements for patients with diabetic macular edema.

A cluster of COVID-19 positive patients developed endophthalmitis, and investigators are searching for a link.

Minimally invasive conjunctival surgery option is an efficient procedure.

With intraoperative sustained release steroids, ophthalmologists can eliminate the gambles of patient adherence.

Nine pediatric patients with Leber congenital amaurosis show visual improvement in clinical trials.

Study supports preoperative ocular surface optimization with artificial tears.

All syringes used for intravitreal injections have pros and cons. Some recently marketed and forthcoming products are coming closer to meeting “ideal” criteria.

Change can prove to benefit individuals with diabetes, other comorbidities.

Safety protocols, creative solutions help physicians restore patient traffic to normal during the pandemic.